We are still learning about a drug which has been in clinical usefor the last 200 years, and there may still be much more to learn.Despite its common usage in Britain for rate control in atrialfibrillation, some authorities (especially in North America) havedescribed digoxin as a drug 'whose time has gone' as beta-blockersand calcium antagonists (verapamil, diltiazem) are being regarded asbeing more refficient alternatives. Digoxin has recently beenre-visited for its role in heart failure; while the value of digoxinin patents with heart failure who have atrial fibrilla- tion has longbeen recognized, its efficacy in those who have sinus rhythm hasoften been questioned, at least until recently.
展开▼
